Ex Vivo Critical Care Glucose Monitor
Scientific and clinical studies have demonstrated that tight control
of blood glucose significantly improves critical care patient outcomes.
Market Need: Scientific and clinical studies have demonstrated
that tight control of blood glucose significantly improves critical
care patient outcomes. Tight glycemic control has been shown to
reduce surgical site infections in cardiothoracic surgery patients,
and has been shown to reduce morbidity, length of stay, and mortality
among ICU patients. Historically, hyperglycemia was treated only
when glucose levels exceeded 220 mg/dL. Based upon these recent
compelling studies, experts now recommend controlling blood glucose
to the normoglycemic range (80–110 mg/dL). Adherence to such strict
glucose control regimens requires near-continuous monitoring of
blood glucose to achieve normoglycemia while avoiding risk of hypoglycemia.
Proposed Solution: InLight is developing a reagentless, easy-to-use,
near-continuous glucose monitoring system that will enable tight
glucose control protocols. A sterile and disposable bloodsampling
system with an integrated optical cuvette is used to make the glucose
determination. The blood-sampling system can be incorporated into
the cardiopulmonary bypass circuit (for cardiac surgery patients),
or can be attached to a standard blood-access catheter (for ICU
patients). The system automatically draws blood into the cuvette,
where glucose concentration is measured by quantitative near-infrared
spectroscopy. Blood is returned to the patient after measurement.
Once the instrument is set up, near-continuous measurements are
made with no further nurse or perfusionist involvement.
Competitive Landscape: Current ICU glucose monitoring requires
multiple finger sticks that are labor intensive, expensive, and
involve blood loss. InLight’s solution has a minimal cost per test,
no calibration, no ongoing labor requirements, and no progressive
blood loss, resulting in true market differentiation.
Development / Commercialization Plan: InLight has demonstrated
near-infrared measurements of glucose in serum and blood with clinical
accuracy. Product realization will require customization of existing
for ex vivo blood measurements and development of the blood sampling
system. InLight will work with clinicians in the OR and ICU settings
to generate clinical feasibility data in patients. InLight’s commercialization
strategy is to partner with patient monitoring market leaders to
introduce the instrument first into the operating room followed
by the critical care hospital setting. Peerreviewed publications
and securing of federal grants will raise clinician and public awareness
that will speed market adoption.
For information on critical care monitoring please follow this link to LuminousMedical.com